Multiple Sclerosis Diagnosis and Treatment
Multiple Sclerosis Diagnosis and Treatment
English[eng]
9783040000000
multiple sclerosis||genetics||disease modifying therapies||generic medicines||association study||reactive oxygen species||NADPH oxidase||CYBB||autoimmunity||axon||cortex||demyelination||mitochondria||myelin||neurodegeneration||oligodendrocyte||progressive multiple sclerosis||daclizumab||relapsing multiple sclerosis||CD25||innate immune system||interleukin-2||drug reaction with eosinophilia systemic symptoms||DRESS||monoclonal antibodies||anti-CD20||Ocrevus||Rituxan||Tysabri||clinical trial||disease modifying therapy||demyelinating diseases||cognitive impairment||cognitive dysfunction||stem cells||autologous hematopoietic||mesenchymal||neuronal||induced pluripotent||human embryonic||pregnancy||post-partum||treatment||neuromyelitis optica spectrum disorders||anti-MOG syndrome||aquaporin 4-IgG||myelin oligodendrocyte glycoprotein||remyelination||outcome measures||biomarkers
English[eng]
9783040000000
multiple sclerosis||genetics||disease modifying therapies||generic medicines||association study||reactive oxygen species||NADPH oxidase||CYBB||autoimmunity||axon||cortex||demyelination||mitochondria||myelin||neurodegeneration||oligodendrocyte||progressive multiple sclerosis||daclizumab||relapsing multiple sclerosis||CD25||innate immune system||interleukin-2||drug reaction with eosinophilia systemic symptoms||DRESS||monoclonal antibodies||anti-CD20||Ocrevus||Rituxan||Tysabri||clinical trial||disease modifying therapy||demyelinating diseases||cognitive impairment||cognitive dysfunction||stem cells||autologous hematopoietic||mesenchymal||neuronal||induced pluripotent||human embryonic||pregnancy||post-partum||treatment||neuromyelitis optica spectrum disorders||anti-MOG syndrome||aquaporin 4-IgG||myelin oligodendrocyte glycoprotein||remyelination||outcome measures||biomarkers